Buprenorphine, Screen
CPT Code(s):
80307
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
5.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present. Preservative (speckled top) tube.
Stability Criteria
Room Temperature:
5 days
Refrigerated:
5 days
Frozen:
30 days
Clinical Significance
Buprenorphine Screen using immunoassay holds specific clinical significance and diagnostic use in the field of toxicology and drug screening. This test is designed to detect the presence of buprenorphine, a medication primarily used for opioid addiction treatment, in a patient's urine or other body fluids.
The clinical significance and diagnostic use of Buprenorphine Screen using immunoassay include:
1. Medication Compliance Monitoring: Buprenorphine Screen helps monitor patient compliance with buprenorphine treatment regimens. Buprenorphine is prescribed as part of medication-assisted treatment (MAT) programs for individuals with opioid addiction. By detecting the presence of buprenorphine in a patient's urine, the test provides objective evidence of recent buprenorphine use, assisting healthcare providers in assessing patient adherence to the prescribed medication.
2. Differentiation from Other Opioids: Buprenorphine Screen aids in differentiating buprenorphine use from the use of other opioids. Buprenorphine is a partial opioid agonist with unique pharmacological properties. The test's specificity to buprenorphine allows healthcare providers to confirm its presence, distinguishing it from other opioids, such as heroin or prescription opioids, that may be detected by general opioid screening tests.
3. Detection of Illicit Buprenorphine Use: Buprenorphine Screen is useful in detecting the presence of buprenorphine in a patient's urine, providing valuable information about illicit drug use. Buprenorphine can be misused or diverted for non-medical purposes. The test assists in identifying individuals who may be using buprenorphine illicitly or without a prescription, allowing healthcare providers to address potential misuse and provide appropriate interventions.
4. Workplace and Legal Drug Testing: Buprenorphine Screen has applications in workplace and legal druging programs. These tests are conducted to ensure a drug-free environment, evaluate compliance with drug rehabilitation programs, or provide evidence in legal proceedings. By detecting the presence of buprenorphine, the test assists in determining compliance or identifying potential illicit drug use.
It is important to note that Buprenorphine Screen using immunoassay provides a qualitative result, indicating the presence or absence of buprenorphine above a specific threshold. If a positive result is obtained, further confirmatory testing using more specific methods, such as liquid chromatography-tandem mass spectrometry (LC/MS-MS), is typically performed to confirm the presence of buprenorphine and provide additional information.
In summary, Buprenorphine Screen using immunoassay has clinical significance in toxicology and drug screening. It aids in monitoring medication compliance, differentiating buprenorphine use from other opioids, detecting illicit buprenorphine use, and supports workplace and legal drug testing programs. By detecting the presence of buprenorphine, this test provides valuable information for clinical decision-making, ensuring treatment adherence, and identifying potential misuse of buprenorphine.
CPT Code(s):
80307
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
5.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present. Preservative (speckled top) tube.
Stability Criteria
Room Temperature:
5 days
Refrigerated:
5 days
Frozen:
30 days
Clinical Significance
Buprenorphine Screen using immunoassay holds specific clinical significance and diagnostic use in the field of toxicology and drug screening. This test is designed to detect the presence of buprenorphine, a medication primarily used for opioid addiction treatment, in a patient's urine or other body fluids.
The clinical significance and diagnostic use of Buprenorphine Screen using immunoassay include:
1. Medication Compliance Monitoring: Buprenorphine Screen helps monitor patient compliance with buprenorphine treatment regimens. Buprenorphine is prescribed as part of medication-assisted treatment (MAT) programs for individuals with opioid addiction. By detecting the presence of buprenorphine in a patient's urine, the test provides objective evidence of recent buprenorphine use, assisting healthcare providers in assessing patient adherence to the prescribed medication.
2. Differentiation from Other Opioids: Buprenorphine Screen aids in differentiating buprenorphine use from the use of other opioids. Buprenorphine is a partial opioid agonist with unique pharmacological properties. The test's specificity to buprenorphine allows healthcare providers to confirm its presence, distinguishing it from other opioids, such as heroin or prescription opioids, that may be detected by general opioid screening tests.
3. Detection of Illicit Buprenorphine Use: Buprenorphine Screen is useful in detecting the presence of buprenorphine in a patient's urine, providing valuable information about illicit drug use. Buprenorphine can be misused or diverted for non-medical purposes. The test assists in identifying individuals who may be using buprenorphine illicitly or without a prescription, allowing healthcare providers to address potential misuse and provide appropriate interventions.
4. Workplace and Legal Drug Testing: Buprenorphine Screen has applications in workplace and legal druging programs. These tests are conducted to ensure a drug-free environment, evaluate compliance with drug rehabilitation programs, or provide evidence in legal proceedings. By detecting the presence of buprenorphine, the test assists in determining compliance or identifying potential illicit drug use.
It is important to note that Buprenorphine Screen using immunoassay provides a qualitative result, indicating the presence or absence of buprenorphine above a specific threshold. If a positive result is obtained, further confirmatory testing using more specific methods, such as liquid chromatography-tandem mass spectrometry (LC/MS-MS), is typically performed to confirm the presence of buprenorphine and provide additional information.
In summary, Buprenorphine Screen using immunoassay has clinical significance in toxicology and drug screening. It aids in monitoring medication compliance, differentiating buprenorphine use from other opioids, detecting illicit buprenorphine use, and supports workplace and legal drug testing programs. By detecting the presence of buprenorphine, this test provides valuable information for clinical decision-making, ensuring treatment adherence, and identifying potential misuse of buprenorphine.
CPT Code(s):
80307
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
5.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present. Preservative (speckled top) tube.
Stability Criteria
Room Temperature:
5 days
Refrigerated:
5 days
Frozen:
30 days
Clinical Significance
Buprenorphine Screen using immunoassay holds specific clinical significance and diagnostic use in the field of toxicology and drug screening. This test is designed to detect the presence of buprenorphine, a medication primarily used for opioid addiction treatment, in a patient's urine or other body fluids.
The clinical significance and diagnostic use of Buprenorphine Screen using immunoassay include:
1. Medication Compliance Monitoring: Buprenorphine Screen helps monitor patient compliance with buprenorphine treatment regimens. Buprenorphine is prescribed as part of medication-assisted treatment (MAT) programs for individuals with opioid addiction. By detecting the presence of buprenorphine in a patient's urine, the test provides objective evidence of recent buprenorphine use, assisting healthcare providers in assessing patient adherence to the prescribed medication.
2. Differentiation from Other Opioids: Buprenorphine Screen aids in differentiating buprenorphine use from the use of other opioids. Buprenorphine is a partial opioid agonist with unique pharmacological properties. The test's specificity to buprenorphine allows healthcare providers to confirm its presence, distinguishing it from other opioids, such as heroin or prescription opioids, that may be detected by general opioid screening tests.
3. Detection of Illicit Buprenorphine Use: Buprenorphine Screen is useful in detecting the presence of buprenorphine in a patient's urine, providing valuable information about illicit drug use. Buprenorphine can be misused or diverted for non-medical purposes. The test assists in identifying individuals who may be using buprenorphine illicitly or without a prescription, allowing healthcare providers to address potential misuse and provide appropriate interventions.
4. Workplace and Legal Drug Testing: Buprenorphine Screen has applications in workplace and legal druging programs. These tests are conducted to ensure a drug-free environment, evaluate compliance with drug rehabilitation programs, or provide evidence in legal proceedings. By detecting the presence of buprenorphine, the test assists in determining compliance or identifying potential illicit drug use.
It is important to note that Buprenorphine Screen using immunoassay provides a qualitative result, indicating the presence or absence of buprenorphine above a specific threshold. If a positive result is obtained, further confirmatory testing using more specific methods, such as liquid chromatography-tandem mass spectrometry (LC/MS-MS), is typically performed to confirm the presence of buprenorphine and provide additional information.
In summary, Buprenorphine Screen using immunoassay has clinical significance in toxicology and drug screening. It aids in monitoring medication compliance, differentiating buprenorphine use from other opioids, detecting illicit buprenorphine use, and supports workplace and legal drug testing programs. By detecting the presence of buprenorphine, this test provides valuable information for clinical decision-making, ensuring treatment adherence, and identifying potential misuse of buprenorphine.